Sight Sciences, Inc.

Sight Sciences, Inc.

SGHTNYSE / NASDAQHealthcareSmall cap

$10.18-$0.44 (-4.1%)

Last close · Data as of Nov 20, 2026

Market cap
$250.3M
P/E
-6.5x
EV / EBITDA
-6.1x
Revenue
$77.4M
Net margin
-49.7%
ROCE
-35.6%

+53.3% over the last year

Sight Sciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+18.1%
3M
+24.9%
6M
+109.5%
1Y
+53.3%
5Y
Hidden
  • This period includes a one-day price step on 26 Oct 2023 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.44 (-4.1%) from $10.62 to $10.18 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SGHT, bought on each weekday since 2021.

News & filings

What Sight Sciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 38.4 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.

Read moreShow less

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Sector
Healthcare
Shares outstanding
53.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$250.3M
P/E
-6.5x
P/B
3.9x
EV / EBITDA
-6.1x
EV / Sales
2.6x
P/S
3.2x
52-week high
$11.01
52-week low
$3.45

Profitability

Operating margin
-48.0%
Net margin
-49.7%
EBITDA margin
-42.4%
ROE
-60.1%
ROCE
-35.6%
ROIC
-206.1%
ROA
-33.3%
Asset turnover
0.67

Growth

Revenue
$77.4M
Revenue growth, 1Y
-3.1%
Revenue CAGR, 3Y
2.7%
Net profit growth, 1Y
-25.4%
Free cash flow
-$29.9M

Solvency

Current ratio
10.22
Debt / Equity
0.64
Debt / Assets
0.35
CFO / Net profit
0.77
Cash / Market cap
36.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$77.4M
Cost of revenue$10.7M
Gross profit$66.7M
Operating expenses$103.8M
Research and development$14.6M
Selling, general and administrative$89.2M
Operating income-$37.1M
Interest and other-$1.3M
Pretax income-$38.4M
Tax and other$10.0k
Net income-$38.4M

Revenue and net profit

Revenue fell 3.1% in FY2025; net profit is the dashed line.

Sight Sciences, Inc. revenue and net profit by fiscal year
Sight Sciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$71.3M-$86.2M
FY2023$81.1M-$55.5M
FY2024$79.9M-$51.5M
FY2025$77.4M-$38.4M

Cash flows

FY2025: -$29.7M from operations, -$29.9M free after investment (dashed).

Sight Sciences, Inc. operating and free cash flow by fiscal year
Sight Sciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$76.0M-$76.9M
FY2023-$47.2M-$48.0M
FY2024-$22.4M-$22.7M
FY2025-$29.7M-$29.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$77.4M-3.1%1Y
EBITDA
-$32.8M
Net profit
-$38.4M
Cash from operations
-$29.7M
Free cash flow
-$29.9M
Revenue CAGR, 3Y
2.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$77.4M-$32.8M-$38.4M-$29.9M-60.1%-3.1%-25.4%

Monthly returns

Month-by-month returns of SGHT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$115.3M
Liabilities$51.4M
Equity$63.9M
Paid-in capital$448.6M
Retained earnings-$384.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SGHT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Sight Sciences, Inc. (this company)2.6x

Not shown (no positive earnings and no EV / Sales): Anavex Life Sciences Corp., Nuvectis Pharma, Inc., Protara Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Sight Sciences, Inc.SGHTthis company$250.3M-6.5x3.9x-60.1%-6.1x
Anavex Life Sciences Corp.AVXL$261.3M-5.6x2.8x-48.9%—
Akebia Therapeutics, Inc.AKBA$260.3M-48.7x8.0x-16.4%5.9x
Fate Therapeutics, Inc.FATE$257.6M-1.9x1.2x-65.8%-2.1x
Nuvectis Pharma, Inc.NVCT$256.5M-9.7x13.9x-143.6%—
Codexis, Inc.CDXS$254.5M-5.8x5.0x-87.0%-8.2x
Protara Therapeutics, Inc.TARA$247.9M-4.3x1.3x-29.2%-3.1x
Coherus Oncology, Inc.CHRS$242.9M1.4x4.0x275.4%-1.1x
Treace Medical Concepts, Inc.TMCI$239.4M-4.1x2.7x-67.6%-7.0x
Peer median—-5.0x3.4x-57.3%-2.6x

Year-to-date ROI

SGHT since 1 January, against earlier years.

Historical volatility

SGHT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Sight Sciences, Inc. operating margin by fiscal year
Sight Sciences, Inc. operating margin by fiscal year
DateOperating margin
FY2022-117.7%
FY2023-70.7%
FY2024-63.3%
FY2025-48.0%
LineFY2025
Cost of revenueCost Of Revenue$10.7M
Gross profitGross Profit$66.7M
Operating expensesOperating Expense$103.8M
Research and developmentResearch And Development$14.6M
Selling, general and administrativeSelling General And Administration$89.2M
Total expensesTotal Expenses$114.5M
Pretax incomePretax Income-$38.4M

Learn while you research

Academy chapters picked for Sight Sciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →